Subscribe
Conference Correspondent

Enzalutamide Long-Term Safety and Efficacy in Hormone-Naïve Prostate Cancer

Conference Correspondent - ESMO 2014 - Prostate Cancer

Enzalutamide is approved for the treatment of patients with metastatic castrate-resistant prostate cancer post-docetaxel. In an open-label phase 2 study in patients with hormone-naïve prostate cancer (HNPC), enzalutamide monotherapy resulted in a high prostate-specific antigen (PSA) response rate, stable bone mineral density (BMD), and improved quality of life (QOL) after 6 and 12 months of treatment, even in patients with metastatic disease at baseline (Tombal B, et al. Lancet Oncol. 2014;15:592-600). At ESMO 2014, Tombal and colleagues reported 2-year data from this study (Tombal B, et al. ESMO 2014: Abstract 766PD).

In this study, 67 patients with HNPC and noncastrate levels of testosterone (≥730 ng/dL) received enzalutamide 160 mg daily until disease progression or unacceptable toxicity. At baseline, 39% of the patients had metastatic disease. At 2 years, 45 patients continue with enzalutamide therapy, and 100% of them had a ≥80% decline in PSA level. Of the 26 patients with metastases at baseline, 50% had a complete response and 15% had a partial response at 2 years. QOL data from the EORTC-QLQ C30 trial showed maintenance of global health status through 2 years, although clinically meaningful deteriorations were reported on the fatigue and the role-functioning scales. The most common treatment-related adverse events reported over the 2-year treatment span were gynecomastia, fatigue, nipple pain, and hot flush. Total body BMD and lean body mass were only slightly decreased at 2 years (-0.39% and -5.27%, respectively).

Tombal and colleagues concluded that enzalutamide monotherapy is associated with significant long-term reductions in PSA levels and a good tumor response in men with HNPC, without adversely affecting total body BMD or global health status.

Related Items
Emerging Agents for Metastatic Prostate Cancer: Galeterone, Selinexor, and ARN-509
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Early PSA Response as a Prognostic Factor in Metastatic Prostate Cancer
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Adding Docetaxel to ADT Significantly Improves Survival versus ADT Alone in Patients with High-Volume Metastatic Prostate Cancer
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Androgen Receptor and CYP17A1 Copy Number Variations as Predictors of Outcomes in Patients with Metastatic Prostate Cancer Receiving Abiraterone
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Updated STRIDE and STAND Trial Results: Optimal Sipuleucel-T Use in Metastatic Prostate Cancer
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
AR-V7 Splice Variant as Prognostic Marker for Resistance to Enzalutamide or Abiraterone in Men with Metastatic Prostate Cancer
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Chemohormonal Therapy versus Hormonal Therapy Alone in Men with Metastatic Prostate Cancer
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Maximal Androgen Depletion with Abiraterone Acetate Followed by Molecular-Targeted Therapies in Metastatic Prostate Cancer: Finding an Androgen-Signaling Signature to Predict Response
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Sequencing Abiraterone Acetate, Cabazitaxel, and Enzalutamide in Post-Docetaxel mCRPC: Exploiting Efficacy and Avoiding Cross-Resistance
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Prognostic Factors for Sequencing Abiraterone, Cabazitaxel, and Enzalutamide in the Post-Docetaxel Setting
Conference Correspondent published on September 28, 2014 in ESMO 2014 - Prostate Cancer
Last modified: July 9, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology